samedan logo

 
 
spacer
home > ebr > spring 2003 > where to biomanufacture? one state's efforts to answer the question
PUBLICATIONS
European Biopharmaceutical Review

Where to Biomanufacture? One State's Efforts to Answer the Question

Where will your company manufacture its next biopharmaceutical product for the North American market? This is a question that looms large for the biotechnology and pharmaceutical industries because an estimated 1,000 large-molecule drugs are moving through clinical trials and toward the marketplace worldwide, threatening to overwhelm current biomanufacturing capacity. Experts in the industry widely agree there is, and will be for the immediate future, an acute global shortage of capacity to produce these products.

Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

spacer
By Barry D Teater, Director of Corporate Communications at the North Carolina Biotechnology Center

Barry D Teater is in his 17th year with the North Carolina Biotechnology Center, the world's first government-based initiative in biotechnology economic development. He is responsible for the Center's websites, publications, media relations, visitor briefings, trade show exhibits, advertising and related activities.

He holds Bachelor's and Master's degrees in Journalism from Eastern Kentucky University and the University of North Carolina at Chapel Hill, respectively.
 

spacer
Barry D Teater
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

Gerresheimer opens a new plant for the production of pharmaceutical primary plastic packaging in China

Düsseldorf/Changzhou, December 11, 2019 – A new plant for producing plastic pharmaceutical packaging has been set up in the Chinese city of Changzhou to help satisfy the high demand for Gerresheimer’s primary packaging in China in the future. Today the new facility will be officially opened.
More info >>

White Papers

Outsourcing and Insourcing: How Eurofins solves the bio/pharma industry’s challenges associated with meeting drug development timelines and budgets with restricted headcounts

Eurofins BioPharma Product Testing

Pharmaceutical and biopharmaceutical companies face a significant challenge to get their drug products developed and launched quickly, all while keeping development costs down. One of the most common ways for companies to lower development costs is to manage fixed headcounts. But when the same scope of work still needs to be completed by a designated time with fewer staff members, this presents a significant challenge. So, how do bio/pharma companies solve this ever so common challenge of increasing output while decreasing headcount? There are essentially three options: temporary staffing, outsourcing, or insourcing.
More info >>

 
Industry Events

2020 Avoca Quality and Innovation Summit

3-4 June 2020, Amsterdam, The Netherlands

The 2020 Avoca Quality and Innovation Summit will take place 3-4 June 2020, in Amsterdam, The Netherlands.
More info >>

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement